{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:16:30Z","timestamp":1793812590555,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["J.0224.20"],"award-info":[{"award-number":["J.0224.20"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["T.0239.21"],"award-info":[{"award-number":["T.0239.21"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neutropenia and neutrophil dysfunction in glycogen storage disease type 1b (GSD1b) and severe congenital neutropenia type 4 (SCN4), associated with deficiencies of the glucose-6-phosphate\u00a0transporter (G6PT\/SLC37A4) and the phosphatase G6PC3, respectively, are the result of the accumulation of 1,5-anhydroglucitol-6-phosphate in neutrophils. This is an inhibitor of hexokinase made from 1,5-anhydroglucitol (1,5-AG), an abundant polyol in blood. 1,5-AG is presumed to be reabsorbed in the kidney by a sodium-dependent-transporter of uncertain identity, possibly SGLT4\/\n                    <jats:italic>SLC5A9<\/jats:italic>\n                    or SGLT5\/\n                    <jats:italic>SLC5A10<\/jats:italic>\n                    . Lowering blood 1,5-AG with an SGLT2-inhibitor greatly improved neutrophil counts and function in G6PC3-deficient and GSD1b patients. Yet, this effect is most likely mediated indirectly, through the inhibition of the renal 1,5-AG transporter by glucose, when its concentration rises in the renal tubule following inhibition of SGLT2. To identify the 1,5-AG transporter, both human and mouse SGLT4 and SGLT5 were expressed in HEK293T cells and transport measurements were performed with radiolabelled compounds. We found that SGLT5 is a better carrier for 1,5-AG than for mannose, while the opposite is true for human SGLT4. Heterozygous variants in SGLT5, associated with a low level of blood 1,5-AG in humans cause a 50\u2013100% reduction in 1,5-AG transport activity tested in model cell lines, indicating that SGLT5 is the predominant kidney 1,5-AG transporter. These and other findings led to the conclusion that (1) SGLT5 is the main renal transporter of 1,5-AG; (2) frequent heterozygous mutations (allelic frequency\u2009&gt;\u20091%) in SGLT5 lower blood 1,5-AG, favourably influencing neutropenia in G6PC3 or G6PT deficiency; (3) the effect of SGLT2-inhibitors on blood 1,5-AG level is largely indirect; (4) specific SGLT5-inhibitors would be more efficient to treat these neutropenias than SGLT2-inhibitors.\n                  <\/jats:p>","DOI":"10.1007\/s00018-023-04884-8","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:14:20Z","timestamp":1692339260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia"],"prefix":"10.1007","volume":"80","author":[{"given":"Jennifer","family":"Diederich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mounkoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan A.","family":"Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Van Schaftingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2968-7374","authenticated-orcid":false,"given":"Maria","family":"Veiga-da-Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"4884_CR1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/00365518209168111","volume":"42","author":"E Pitkanen","year":"1982","unstructured":"Pitkanen E (1982) Serum 1,5-anhydroglucitol in normal subjects and in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 42:445\u2013448","journal-title":"Scand J Clin Lab Invest"},{"key":"4884_CR2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.1816143116","volume":"116","author":"M Veiga-da-Cunha","year":"2019","unstructured":"Veiga-da-Cunha M, Chevalier N, Stephenne X, Defour JP, Paczia N, Ferster A, Achouri Y, Dewulf JP, Linster CL, Bommer GT, Van Schaftingen E (2019) Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proc Natl Acad Sci USA 116:1241\u20131250","journal-title":"Proc Natl Acad Sci USA"},{"key":"4884_CR3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood.2019004465","volume":"136","author":"SB Wortmann","year":"2020","unstructured":"Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M (2020) Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood 136:1033\u20131043","journal-title":"Blood"},{"key":"4884_CR4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jimd.12509","volume":"45","author":"C Boulanger","year":"2022","unstructured":"Boulanger C, Stephenne X, Diederich J, Mounkoro P, Chevalier N, Ferster A, Van Schaftingen E, Veiga-da-Cunha M (2022) Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: impact of a mutation in SGLT5. J Inherit Metab Dis 45:759\u2013768","journal-title":"J Inherit Metab Dis"},{"key":"4884_CR5","doi-asserted-by":"crossref","unstructured":"Veiga-da-Cunha, M, Van Schaftingen, E and Bommer, GT. (2019) Inborn errors of metabolite repair. J Inherit Metab Dis","DOI":"10.1002\/jimd.12187"},{"key":"4884_CR6","doi-asserted-by":"crossref","unstructured":"Veiga-da-Cunha, M, Wortmann, SB, Grunert, SC and Van Schaftingen, E. (2023) Treatment of the neutropenia associated with GSD1b and G6PC3 deficiency with SGLT2 inhibitors. Diagnostics (Basel) 13","DOI":"10.3390\/diagnostics13101803"},{"key":"4884_CR7","first-page":"E268","volume":"263","author":"T Yamanouchi","year":"1992","unstructured":"Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, Miyashita H, Akaoka I (1992) Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 263:E268-273","journal-title":"Am J Physiol"},{"key":"4884_CR8","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/diacare.27.8.1859","volume":"27","author":"JB McGill","year":"2004","unstructured":"McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ, assay, UStotG (2004) Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care. 27:1859\u20131865","journal-title":"Diabetes Care."},{"issue":"Suppl","key":"4884_CR9","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/0168-8227(94)90259-3","volume":"24","author":"T Yamanouchi","year":"1994","unstructured":"Yamanouchi T, Akanuma Y (1994) Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 24(Suppl):S261-268","journal-title":"Diabetes Res Clin Pract"},{"key":"4884_CR10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2337\/diab.38.6.723","volume":"38","author":"T Yamanouchi","year":"1989","unstructured":"Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, Akaoka I (1989) Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 38:723\u2013729","journal-title":"Diabetes"},{"key":"4884_CR11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/BF00277486","volume":"31","author":"Y Akanuma","year":"1988","unstructured":"Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H (1988) Urinary excretion of 1,5-anhydro-d-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 31:831\u2013835","journal-title":"Diabetologia"},{"key":"4884_CR12","first-page":"3641","volume":"124","author":"J Sun","year":"2011","unstructured":"Sun J, Dou JT, Wang XL, Yang GQ, Lu ZH, Zheng H, Ma FL, Lu JM, Mu YM (2011) Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin Med J (Engl) 124:3641\u20133645","journal-title":"Chin Med J (Engl)"},{"key":"4884_CR13","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.470","volume":"11","author":"BA Kappel","year":"2021","unstructured":"Kappel BA, Moellmann J, Thiele K, Rau M, Artati A, Adamski J, Ghesquiere B, Schuett K, Romeo F, Stoehr R, Marx N, Federici M, Lehrke M (2021) Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker. Clin Transl Med 11:e470","journal-title":"Clin Transl Med"},{"key":"4884_CR14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.gim.2022.04.001","volume":"24","author":"SC Grunert","year":"2022","unstructured":"Grunert SC, Derks TGJ, Adrian K, Al-Thihli K, Ballhausen D, Bidiuk J, Bordugo A, Boyer M, Bratkovic D, Brunner-Krainz M, Burlina A, Chakrapani A, Corpeleijn W, Cozens A, Dawson C, Dhamko H, Milosevic MD, Eiroa H, Finezilber Y, Moura de Souza CF, Garcia-Jimenez MC, Gasperini S, Haas D, Haberle J, Halligan R, Fung LH, Horbe-Blindt A, Horka LM, Huemer M, Ucar SK, Kecman B, Kilavuz S, Krivan G, Lindner M, Lusebrink N, Makrilakis K, Mei-Kwun Kwok A, Maier EM, Maiorana A, McCandless SE, Mitchell JJ, Mizumoto H, Mundy H, Ochoa C, Pierce K, Fraile PQ, Regier D, Rossi A, Santer R, Schuman HC, Sobieraj P, Spenger J, Spiegel R, Stepien KM, Tal G, Tansek MZ, Torkar AD, Tchan M, Thyagu S, Schrier Vergano SA, Vucko E, Weinhold N, Zsidegh P, Wortmann SB (2022) Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire. Genet Med 24:1781\u20131788","journal-title":"Genet Med"},{"key":"4884_CR15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jmd2.12278","volume":"63","author":"M Kaczor","year":"2022","unstructured":"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczynska-Seliga E, Ciara E, Piatosa B, Rokicki D, Ksiazyk J, Wesol-Kucharska D (2022) Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b? JIMD Rep. 63:199\u2013206","journal-title":"JIMD Rep."},{"key":"4884_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","volume":"17","author":"RK Halligan","year":"2022","unstructured":"Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR (2022) Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre. Orphanet J Rare Dis 17:195","journal-title":"Orphanet J Rare Dis"},{"key":"4884_CR17","doi-asserted-by":"crossref","first-page":"1071464","DOI":"10.3389\/fped.2022.1071464","volume":"10","author":"Z Hexner-Erlichman","year":"2022","unstructured":"Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag AD, Tatour S, Spiegel R (2022) Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Front Pediatr 10:1071464","journal-title":"Front Pediatr"},{"key":"4884_CR18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.lfs.2004.10.016","volume":"76","author":"S Tazawa","year":"2005","unstructured":"Tazawa S, Yamato T, Fujikura H, Hiratochi M, Itoh F, Tomae M, Takemura Y, Maruyama H, Sugiyama T, Wakamatsu A, Isogai T, Isaji M (2005) SLC5A9\/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose. Life Sci 76:1039\u20131050","journal-title":"Life Sci"},{"key":"4884_CR19","first-page":"435","volume":"38","author":"H Saito","year":"1996","unstructured":"Saito H, Ohtomo T, Inui K (1996) Na(+)-dependent uptake of 1,5-anhydro-d-glucitol via the transport systems for D-glucose and D-mannose in the kidney epithelial cell line, LLC-PK1. Nihon Jinzo Gakkai Shi 38:435\u2013440","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"4884_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167464","volume":"434","author":"K Kamitori","year":"2022","unstructured":"Kamitori K, Shirota M, Fujiwara Y (2022) Structural basis of the selective sugar transport in sodium-glucose cotransporters. J Mol Biol 434:167464","journal-title":"J Mol Biol"},{"key":"4884_CR21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/s41598-017-02287-x","volume":"7","author":"M Li","year":"2017","unstructured":"Li M, Maruthur NM, Loomis SJ, Pietzner M, North KE, Mei H, Morrison AC, Friedrich N, Pankow JS, Nauck M, Boerwinkle E, Teumer A, Selvin E, Kottgen A (2017) Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci Rep 7:2812","journal-title":"Sci Rep"},{"key":"4884_CR22","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1038\/s41598-019-42202-0","volume":"9","author":"SJ Loomis","year":"2019","unstructured":"Loomis SJ, Kottgen A, Li M, Tin A, Coresh J, Boerwinkle E, Gibbs R, Muzny D, Pankow J, Selvin E, Duggal P (2019) Rare variants in SLC5A10 are associated with serum 1,5-anhydroglucitol (1,5-AG) in the atherosclerosis risk in communities (ARIC) study. Sci Rep 9:5941","journal-title":"Sci Rep"},{"key":"4884_CR23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ng.3809","volume":"49","author":"T Long","year":"2017","unstructured":"Long T, Hicks M, Yu HC, Biggs WH, Kirkness EF, Menni C, Zierer J, Small KS, Mangino M, Messier H, Brewerton S, Turpaz Y, Perkins BA, Evans AM, Miller LA, Guo L, Caskey CT, Schork NJ, Garner C, Spector TD, Venter JC, Telenti A (2017) Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat Genet 49:568\u2013578","journal-title":"Nat Genet"},{"key":"4884_CR24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.febslet.2011.12.027","volume":"586","author":"R Grempler","year":"2012","unstructured":"Grempler R, Augustin R, Froehner S, Hildebrandt T, Simon E, Mark M, Eickelmann P (2012) Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett 586:248\u2013253","journal-title":"FEBS Lett"},{"key":"4884_CR25","doi-asserted-by":"crossref","first-page":"16849","DOI":"10.1073\/pnas.0404840101","volume":"101","author":"R Rzem","year":"2004","unstructured":"Rzem R, Veiga-da-Cunha M, Noel G, Goffette S, Nassogne MC, Tabarki B, Scholler C, Marquardt T, Vikkula M, Van Schaftingen E (2004) A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci USA 101:16849\u201316854","journal-title":"Proc Natl Acad Sci USA"},{"key":"4884_CR26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/nar\/24.4.596","volume":"24","author":"M Jordan","year":"1996","unstructured":"Jordan M, Schallhorn A, Wurm FM (1996) Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucl Acids Res 24:596\u2013601","journal-title":"Nucl Acids Res"},{"key":"4884_CR27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1472-6750-8-91","volume":"8","author":"H Liu","year":"2008","unstructured":"Liu H, Naismith JH (2008) An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol 8:91","journal-title":"BMC Biotechnol"},{"key":"4884_CR28","doi-asserted-by":"crossref","first-page":"11968","DOI":"10.1038\/s41598-017-12210-z","volume":"7","author":"L Ying","year":"2017","unstructured":"Ying L, He X, Ma X, Shen Y, Su H, Peng J, Wang Y, Bao Y, Zhou J, Jia W (2017) Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population. Sci Rep 7:11968","journal-title":"Sci Rep"},{"key":"4884_CR29","volume":"8","author":"T Fukuzawa","year":"2013","unstructured":"Fukuzawa T, Fukazawa M, Ueda O, Shimada H, Kito A, Kakefuda M, Kawase Y, Wada NA, Goto C, Fukushima N, Jishage K, Honda K, King GL, Kawabe Y (2013) SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose. PLoS One 8:e56681","journal-title":"PLoS One"},{"key":"4884_CR30","doi-asserted-by":"crossref","first-page":"C1293","DOI":"10.1152\/ajpcell.00397.2011","volume":"302","author":"M Sala-Rabanal","year":"2012","unstructured":"Sala-Rabanal M, Hirayama BA, Loo DD, Chaptal V, Abramson J, Wright EM (2012) Bridging the gap between structure and kinetics of human SGLT1. Am J Physiol Cell Physiol 302:C1293-1305","journal-title":"Am J Physiol Cell Physiol"},{"key":"4884_CR31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-021-04211-w","volume":"601","author":"L Han","year":"2022","unstructured":"Han L, Qu Q, Aydin D, Panova O, Robertson MJ, Xu Y, Dror RO, Skiniotis G, Feng L (2022) Structure and mechanism of the SGLT family of glucose transporters. Nature 601:274\u2013279","journal-title":"Nature"},{"key":"4884_CR32","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1038\/s41467-022-33421-7","volume":"13","author":"Y Niu","year":"2022","unstructured":"Niu Y, Cui W, Liu R, Wang S, Ke H, Lei X, Chen L (2022) Structural mechanism of SGLT1 inhibitors. Nat Commun 13:6440","journal-title":"Nat Commun"},{"key":"4884_CR33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","volume":"601","author":"Y Niu","year":"2022","unstructured":"Niu Y, Liu R, Guan C, Zhang Y, Chen Z, Hoerer S, Nar H, Chen L (2022) Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Nature 601:280\u2013284","journal-title":"Nature"},{"key":"4884_CR34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596:583\u2013589","journal-title":"Nature"},{"key":"4884_CR35","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, Zidek A, Green T, Tunyasuvunakool K, Petersen S, Jumper J, Clancy E, Green R, Vora A, Lutfi M, Figurnov M, Cowie A, Hobbs N, Kohli P, Kleywegt G, Birney E, Hassabis D, Velankar S (2022) AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucl Acids Res 50:D439\u2013D444","journal-title":"Nucl Acids Res"},{"key":"4884_CR36","first-page":"55","volume":"201","author":"E Pitkanen","year":"1990","unstructured":"Pitkanen E (1990) 1,5-Anhydro-d-glucitol\u2013a novel type of sugar in the human organism. Scand J Clin Lab Invest Suppl 201:55\u201362","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"4884_CR37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00374472","volume":"420","author":"E Pitkanen","year":"1992","unstructured":"Pitkanen E, Pitkanen OM (1992) Renal tubular reabsorption of 1,5-anhydro-d-glucitol and d-mannose in vivo in the rat. Pflugers Arch 420:367\u2013375","journal-title":"Pflugers Arch"},{"key":"4884_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83\u201390","journal-title":"Diabetes Obes Metab"},{"key":"4884_CR39","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1038\/s41598-017-02895-7","volume":"7","author":"BM Ayoub","year":"2017","unstructured":"Ayoub BM, Mowaka S, Elzanfaly ES, Ashoush N, Elmazar MM, Mousa SA (2017) Pharmacokinetic evaluation of empagliflozin in healthy egyptian volunteers using LC-MS\/MS and comparison with other ethnic populations. Sci Rep 7:2583","journal-title":"Sci Rep"},{"key":"4884_CR40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2050-6511-14-26","volume":"14","author":"A Kapur","year":"2013","unstructured":"Kapur A, O\u2019Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James CD Jr, Mikoshiba I, Nunez DJ (2013) First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 14:26","journal-title":"BMC Pharmacol Toxicol"},{"key":"4884_CR41","doi-asserted-by":"crossref","first-page":"F473","DOI":"10.1152\/ajprenal.00247.2018","volume":"316","author":"A Gonzalez-Vicente","year":"2019","unstructured":"Gonzalez-Vicente A, Cabral PD, Hong NJ, Asirwatham J, Saez F, Garvin JL (2019) Fructose reabsorption by rat proximal tubules: role of Na(+)-linked cotransporters and the effect of dietary fructose. Am J Physiol Renal Physiol 316:F473\u2013F480","journal-title":"Am J Physiol Renal Physiol"},{"key":"4884_CR42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0304-4165(96)00050-5","volume":"1291","author":"T Yamanouchi","year":"1996","unstructured":"Yamanouchi T, Shinohara T, Ogata N, Tachibana Y, Akaoka I, Miyashita H (1996) Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim Biophys Acta 1291:89\u201395","journal-title":"Biochim Biophys Acta"},{"key":"4884_CR43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","volume":"28","author":"MJ Coady","year":"2017","unstructured":"Coady MJ, El Tarazi A, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY (2017) MAP17 Is a necessary activator of renal Na+\/glucose cotransporter SGLT2. J Am Soc Nephrol 28:85\u201393","journal-title":"J Am Soc Nephrol"},{"key":"4884_CR44","doi-asserted-by":"crossref","first-page":"F799","DOI":"10.1152\/ajprenal.00149.2003","volume":"285","author":"T Blasco","year":"2003","unstructured":"Blasco T, Aramayona JJ, Alcalde AI, Catalan J, Sarasa M, Sorribas V (2003) Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes. Am J Physiol Renal Physiol 285:F799-810","journal-title":"Am J Physiol Renal Physiol"},{"key":"4884_CR45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cca.2015.11.010","volume":"452","author":"D Fortuna","year":"2016","unstructured":"Fortuna D, McCloskey LJ, Stickle DF (2016) Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol. Clin Chim Acta 452:138\u2013141","journal-title":"Clin Chim Acta"},{"key":"4884_CR46","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/cphy.c210030","volume":"12","author":"V Vallon","year":"2021","unstructured":"Vallon V, Nakagawa T (2021) Renal tubular handling of glucose and fructose in health and disease. Compr Physiol 12:2995\u20133044","journal-title":"Compr Physiol"},{"key":"4884_CR47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13052-021-01100-w","volume":"47","author":"A Rossi","year":"2021","unstructured":"Rossi A, Miele E, Fecarotta S, Veiga-da-Cunha M, Martinelli M, Mollica C, D\u2019Armiento M, Mozzillo E, Strisciuglio P, Derks TGJ, Staiano A, Parenti G (2021) Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. Ital J Pediatr 47:149","journal-title":"Ital J Pediatr"},{"key":"4884_CR48","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40265-019-01150-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Remogliflozin etabonate: first global approval. Drugs 79:1157\u20131161","journal-title":"Drugs"},{"key":"4884_CR49","doi-asserted-by":"crossref","unstructured":"Bommer, GT, Van Schaftingen, E and Veiga-da-Cunha, M. (2019) Metabolite Repair Enzymes Control Metabolic Damage in Glycolysis. Trends Biochem Sci","DOI":"10.1016\/j.tibs.2019.07.004"},{"key":"4884_CR50","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/iub.125","volume":"60","author":"S Yu","year":"2008","unstructured":"Yu S (2008) The anhydrofructose pathway of glycogen catabolism. IUBMB Life 60:798\u2013809","journal-title":"IUBMB Life"},{"key":"4884_CR51","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1074\/jbc.M113.544064","volume":"289","author":"M Ichikawa","year":"2014","unstructured":"Ichikawa M, Scott DA, Losfeld ME, Freeze HH (2014) The metabolic origins of mannose in glycoproteins. J Biol Chem 289:6751\u20136761","journal-title":"J Biol Chem"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-04884-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-023-04884-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-04884-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:19:37Z","timestamp":1694438377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-023-04884-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4884"],"URL":"https:\/\/doi.org\/10.1007\/s00018-023-04884-8","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"16 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests and have no relevant financial or non-financial interests to disclose","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study did not involve any human or animal subjects and therefore did not need any ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate and consent to publish"}}],"article-number":"259"}}